Evidence map›Paper›PMID 37194936›Full record

Observational studyCurrent rheumatology reviews2023

The Psoriatic Arthritis Experience in Saudi Arabia from the Rheumatologist and Patient Perspectives.

Ibrahim Alhomood, Mohamed Fatani, Mohamed Bedaiwi, Sahar Al Natour, Alper Erdogan, Aya Alsharafi, Suzan Attar

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Current rheumatology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ibrahim AlhomoodMedical Specialities Department, King Fahad Medical City (KFMC), P.O. Box 59046, Riyadh, 11525, Kingdom of Saudi Arabia.
Mohamed FataniDepartment of Dermatology, Heraa Hospital, Al Madinah Al Munawarah Rd, Mecca, Makkah, 24227, Kingdom of Saudi Arabia.ORCID 0000-0002-7461-0595
Mohamed BedaiwiDepartment of Medicine, Rheumatology Unit, College of Medicine, King Saud University, P.O. Box 14511, Riyadh, 11451, Kingdom of Saudi Arabia.
Sahar Al NatourDepartment of Dermatology, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam, 34212, Kingdom of Saudi Arabia.
Alper ErdoganDepartment of Medical Neurology, Eli Lilly and Company, Ulaya Dist., Riyadh, Riyadh Province, Kingdom of Saudi Arabia.
Aya AlsharafiDepartment of Medical Neurology, Eli Lilly and Company, Ulaya Dist., Riyadh, Riyadh Province, Kingdom of Saudi Arabia.
Suzan AttarDepartment of Rheumatology, King Abdulaziz University, P.O. Box 80200, Jeddah, 21589, Kingdom of Saudi Arabia.
Hera General Hospital · SAImam Abdulrahman Bin Faisal University · SAKing Abdulaziz University · SAKing Fahd Medical City · SAKing Saud University · SA

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

backgroundPsoriatic arthritis (PsA) is a musculoskeletal disease that adversely affects physical mobility and quality of life. It is challenging to manage because of the heterogeneous nature of the symptoms and the current treatment options. PURPOSE: To explore the patient and rheumatologist perspectives of PsA to help improve understanding of the disease experience and improve disease management.

methodsA descriptive, observational cross-sectional study of Saudi Arabian dermatologists and rheumatologists and patients with psoriasis or PsA was conducted. Questionnaire data were collected from 31 dermatologists, 34 rheumatologists, 90 patients with psoriasis, and 98 patients with PsA and analysed using descriptive statistics. Here, data from rheumatologists and patients with PsA are presented.

resultsThe results revealed similarities and differences in the rheumatologist and patient perspectives of PsA. Rheumatologists and patients agreed on the impact that PsA had on patients' quality of life and that more education was needed. However, they differed on several aspects of disease management. Rheumatologists estimated the time to diagnosis as four times shorter than what patients experienced. Patients accepted their diagnosis more than rheumatologists perceived them to; rheumatologists perceived patients to be worried or fearful. Patients perceived joint pain as their most severe symptom, in contrast to rheumatologists, who presumed skin appearance was the most severe symptom. Reported input into PsA treatment goals differed significantly. More than half of the rheumatologists reported equal patient-physician input into goal development as opposed to <10% of patients reporting the same. Almost half of patients reported no input into the development of their treatment goals.

conclusionThe management of PsA could benefit from enhanced screening and re-evaluation of what PsA outcomes have the most value to patients and rheumatologists. A multidisciplinary approach is recommended with increased patient involvement in disease management and individualized treatment options.

Indexed as

Arthritis, PsoriaticPsoriasisCross-Sectional StudiesHumansQuality of LifeRheumatologistsSaudi Arabiadisease managementpatient perspectivesPsA treatmentPsoriatic arthritisrheumatologistssurvey

Identifiers

PMID37194936
PMCPMC10523353
OpenAlexW4376871360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.